Skin最新文献

{"title":"A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement","authors":"Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette","doi":"10.25251/skin.7.supp.256","DOIUrl":"https://doi.org/10.25251/skin.7.supp.256","url":null,"abstract":"Introduction: We evaluate safety and efficacy of risankizumab (RZB) vs. placebo (PBO) in adult patients with moderate-to-severe non-pustular palmoplantar psoriasis (PPPsO).&#x0D; Method: IMMprint, a Ph3b study evaluated safety and efficacy of RZB vs. PBO in moderate-to-severe PPPsO patients with a static physician’s global assessment(sPGA) of moderate or severe ≥3, palmoplantar psoriasis area and severity index(PPASI) ≥8 and at least 1 additional PsO plaque. The 52-week treatment was split into period A, patients randomized (1:1) to RZB 150-mg or PBO, and period B, patients continuing RZB or switching from PBO to RZB (PBO/RZB). Primary endpoint was achievement of palmoplantar investigator’s global assessment (ppIGA) 0/1 with at least 2-point reduction from baseline at Wk16. Ranked secondary endpoints include ≥75% &amp; 90% improvement in PPASI (PPASI75, PPASI90), sPGA 0/1 and 100% improvement in PPASI(PPASI100) at Wk16.&#x0D; Results: Of 174 enrolled, 87(mean age[SD]: 56.9[12.9] years) were randomized to RZB and 87(mean age[SD]: 53.9[14.3] years) were randomized to PBO. Baseline characteristics were similar except for numerical difference in PsA (RZB vs. PBO: 11.5% vs 4.6%, respectively). At Wk16, a significantly higher proportion receiving RZB achieved ppIGA 0/1 than PBO(33.3% vs. 16.1%, p = 0.006). Patients receiving RZB also demonstrated significantly higher responses than patients receiving PBO in all ranked secondary endpoints: PPASI75 (42.5% vs 14.9%, P < 0.001); PPASI90 (27.6% vs 5.7%, p<0.001); sPGA 0/1 (32.2% vs 11.5%, p < 0.001); and PPASI100 (17.2% vs. 1.1%, p < 0.001). Four patients (3 RZB: 1 PBO) discontinued drug in period A. At Wk52, ppIGA 0/1 was achieved by 50.6% of RZB patients and 61.7% of PBO/RZB group. Proportion of patients achieving PPASI75 at Wk52 was 57.5%(RZB) vs. 65.4% (PBO/RZB). Achievement of sPGA 0/1 (%RZB vs. %PBO/RZB) was 43.7% vs. 66.7%; PPASI100 was achieved by 26.4% (RZB) and 37.0% (PBO/RZB) patients at Wk52. Proportion of patients with adverse events were 29.1%(RZB) and 23.0%(PBO) in period A, and 49.4%(RZB) and 35.8% (PBO/RZB) in period B. One RZB patient with prior cardiovascular risk factors had an adjudicated myocardial infarction and subsequently died after 140-day follow-up period. The number of patients with COVID-19 were 3 (RZB; 1 serious infection) and 2(PBO) in period A and 11 (RZB) and 7 (PBO/RZB) in period B.&#x0D; Conclusion: This study demonstrates RZB can provide effective improvement compared to PBO by Wk16 with continuous improvement until Wk52 with no new safety signals in patients with moderate-to-severe PPPsO.","PeriodicalId":86868,"journal":{"name":"Skin","volume":"69 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment or Psoriasis with Calcipotriene and Betamethasone Dipropionate (CAL/BDP) Cream Showed Significantly Higher Proportion of Patients with an Absolute mPASI≤2 Compared to CAL/BDP Gel/Topical Suspension in a Post-Hoc Aanalysis of Two Phase 3 Studies","authors":"April Armstrong, Anna Campanati, Lars Iversen, Morten Praestegaard, José Luis López Estebaranz","doi":"10.25251/skin.7.supp.233","DOIUrl":"https://doi.org/10.25251/skin.7.supp.233","url":null,"abstract":"","PeriodicalId":86868,"journal":{"name":"Skin","volume":"69 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lebrikizumab Delivers Clinically Meaningful and Continuous Improvement in Itch-Free Days in Atopic Dermatitis Through One Year","authors":"Gil Yosipovitch, Claudia Zeidler, Christian J. Apfelbacher, Vivian Laquer, Brian S. Kim, Marta Casillas, Evangeline Pierce, Sherry Chen, Meihua Qiao, Helena Agell, James Del Rosso","doi":"10.25251/skin.7.supp.273","DOIUrl":"https://doi.org/10.25251/skin.7.supp.273","url":null,"abstract":"","PeriodicalId":86868,"journal":{"name":"Skin","volume":"3 11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Outcomes Analysis: The Evolution and Growth of a Teledermatology Program to Accommodate High Patient Volumes","authors":"Leandra Doan, Marit Kreidel, MD, Jeffrey Benabio, MD, MBA, Gabriel Hernandez, BS, Walt Engler, BS, Linda Tolbert, MD, JD, EdD, MPH","doi":"10.25251/skin.7.6.2","DOIUrl":"https://doi.org/10.25251/skin.7.6.2","url":null,"abstract":"Background: Most teledermatology studies include reviews of programs on a limited scale, whereas there are fewer reports on how to expand a program to accommodate high patient volumes.&#x0D; Objective: To share our insights into the growth and maintenance of a teledermatology program that sees over 100,000 cases a year. &#x0D; Methods: Retrospective review of a teledermatology program between 2015 and 2022. Outcomes were compared between the initial phase from 2015-2017 and the maturation phase from 2018-2022.&#x0D; Results: In 2015, the teledermatology program was piloted in 3 hospital centers and expanded to 10 more centers by 2017. There was a total of 12,385 cases in 2015, which increased to 139,110 cases in 2022. Despite the dramatic increase in number of cases, our program adapted well: the initial phase of program development resulted in 69.2% of concerns being treated remotely, compared to 70.9% of submissions in the later years, p <0.001.&#x0D; Limitations: Overall generalizability as this study was performed in a large integrated health system.&#x0D; Discussion: We maintain that the following can help scale a teledermatology program: 1. Communication with all interested parties; 2. Streamlined implementation of technological devices; 3. Training for dermatologists and primary providers; 4. Image guidelines to maintain photo quality.","PeriodicalId":86868,"journal":{"name":"Skin","volume":"9 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs Appropriate Use Criteria Scores and Treatment of Keratinocyte Carcinoma: Review of 11,145 Tumors","authors":"Richard H. Hope, Travis S. Dowdle, Landon Hope, Corley Pruneda","doi":"10.25251/skin.7.6.3","DOIUrl":"https://doi.org/10.25251/skin.7.6.3","url":null,"abstract":"Background: Various methods are available for treatment of keratinocyte carcinomas (KCs). The Mohs appropriate use criteria (AUC) score was developed to quantify the appropriateness of Mohs micrographic surgery (MMS) based on multiple tumor and patient characteristics. Objectives: Stratify KCs by treatment modality used and compare to Mohs AUC score. Methods: Conducted a retrospective review of 11,145 consecutive KCs between 01/2017 and 12/2021, comparing associated Mohs AUC score with modality selected. Results: The average Mohs AUC score for all KCs combined was 7.1 with 8714 (78.2%) qualifying for MMS via AUC score. However, MMS was only done on 2813 (32.3%) of KCs. Excisional surgery was used to treat 4580 (41.1%) of KCs, 2777 (24.9%) were treated with electrodesiccation and curettage (ED&amp;C), and 732 (6.6%) were treated with biopsy only. Of those KCs treated with excision, ED&amp;C, or a biopsy, 70.7%, 70.7%, and 72.4% reached an “appropriate” Mohs AUC score for MMS respectively. Limitations: This is a single private practice, with two board certified dermatologists Conclusions: Mohs AUC score can help determine if a KC warrants MMS; however, in our practice, MMS was necessary for only 32.3% of the KCs that qualified based on the Mohs AUC score.","PeriodicalId":86868,"journal":{"name":"Skin","volume":"57 17","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136283403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age","authors":"Jonathan I. Silverberg, Lawrence F. Eichenfield, Adelaide A. Hebert, Eric Simpson, Linda Stein Gold, Robert Bissonnette, Kim A. Papp, John Browning, Pearl Kwong, Neil J. Korman, Philip M. Brown, David S. Rubenstein, Stephen C. Piscitelli, Matthew C. Somerville, Anna Tallman, Leon Kircik","doi":"10.25251/skin.7.supp.283","DOIUrl":"https://doi.org/10.25251/skin.7.supp.283","url":null,"abstract":"","PeriodicalId":86868,"journal":{"name":"Skin","volume":"57 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136283406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma","authors":"Neal Bhatia, Jonathan Kantor, Lawrence Green, Jonathan Weiss, Cynthia Willson, Susan Cutler, Jayson Rieger, David K. Glover, Pamela Rumney, Gary Goldenberg","doi":"10.25251/skin.7.supp.260","DOIUrl":"https://doi.org/10.25251/skin.7.supp.260","url":null,"abstract":"<jats:p />","PeriodicalId":86868,"journal":{"name":"Skin","volume":"56 20","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136283418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Remission of Refractory Plantar Warts with Cantharidin Plus in an Immunosuppressed Patient","authors":"Afsoon Ghafari-Saravi","doi":"10.25251/skin.7.5.13","DOIUrl":"https://doi.org/10.25251/skin.7.5.13","url":null,"abstract":"Organ transplant patients on immunosuppressive therapies are susceptible to developing refractory human papillomavirus (HPV) infections including cutaneous warts. These warts are known to respond to conservative treatment modalities in the immunocompetent but are often refractory to multiple treatments in the immunosuppressed. Here we report a case of an immunosuppressed adult with plantar warts recalcitrant to numerous therapies that was ultimately treated successfully with cantharidin-podophyllotoxin-salicylic acid (CPS) monotherapy. After 19 treatment sessions over a 16-month time period, complete resolution was achieved. CPS may be a promising treatment modality in cases of severe, refractory verruca plantaris such as those seen in our immunosuppressed patient.","PeriodicalId":86868,"journal":{"name":"Skin","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135395980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypopigmented Plaques Arising in a Tattoo","authors":"Harrison Zhu, Abdul Hafeez Diwan, Vicky Ren","doi":"10.25251/skin.7.5.20","DOIUrl":"https://doi.org/10.25251/skin.7.5.20","url":null,"abstract":"A man in his 40s with a remote history of thyroidectomy for noncancerous thyroid nodules presented with an asymptomatic rash on his left chest tattoo. The rash had started 18 months after tattoo placement and gradually spread the year prior to presentation. Examination revealed bluishwhite, atrophic papules coalescing into plaques in the inferolateral and superolateral aspects of a multicolored tattoo (Figure 1). The patient denied rash elsewhere, including the genitals, and declined further physical examination. Histopathologic examination of a punch biopsy showed compact hyperkeratosis, epidermal atrophy with effaced rete ridges and vacuolar degeneration, and papillary dermal pallor overlying tattoo pigment and pigment incontinence (Figure 2).","PeriodicalId":86868,"journal":{"name":"Skin","volume":"240 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135395981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zosteriform Cutaneous Manifestation of Ovarian Adenocarcinoma Metastasis to the Breast","authors":"Alyssa Hansen, Victor Teran, Brent Kelly, Michael Wilkerson","doi":"10.25251/skin.7.5.17","DOIUrl":"https://doi.org/10.25251/skin.7.5.17","url":null,"abstract":"A 78-year-old Asian female presented via telemedicine during the COVID-19 pandemic for evaluation of a rash on her left breast, present for two weeks. Past medical history includes recurrent ovarian papillary serous adenocarcinoma and abdominal carcinomatosis status post multiple surgical interventions and rounds of chemotherapy. The patient noted the rash started suddenly and was asymptomatic. Physical exam demonstrated scattered erythematous papules coalescing into plaques on the left breast in a dermatomal distribution and a single erythematous blister on the superior left areolae. The patient was started empirically on valacyclovir for suspected herpes zoster infection.","PeriodicalId":86868,"journal":{"name":"Skin","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135395838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}